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Abstract
Varicella vaccines are highly immunogenic, efﬁcacious and safe in preventing varicella disease. The USA has been the ﬁrst country
recommending universal vaccination. In the European Union/European Economic Area countries, the use of varicella vaccine is
heterogeneous, with some countries recommending universal vaccination in children at national or regional level, others only in high-risk
groups and others having no recommendation at all. Uncertainties on the potential impact of varicella vaccination on the epidemiology of
varicella and herpes zoster still exist. These uncertainties are the main reason behind the diverse vaccine recommendations. Surveillance
systems and mathematical models could be useful to address these uncertainties. However, the lack of surveillance of varicella and herpes
zoster in some countries, as well as the high variability of surveillance systems in the countries that have one, makes it difﬁcult to assess the
effect of the vaccine. On the other hand, mathematical models are based on assumptions and should be interpreted carefully. Continuous
surveillance of varicella and herpes zoster is needed to identify any changes in the epidemiological presentation of the diseases. In any case,
continuous surveillance will be needed to fully describe the impact of the programmes currently running and clarify some of the actual
uncertainties in the near future. Additionally, increasing our understanding of the risk factors for development of herpes zoster is required.
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This article is based on the presentation ‘Chickenpox vaccination: a
laboured take off’ given at the 2nd ESCMID Conference on The
Impact of Vaccines on Public Health [1].
Varicella
Varicella is an acute infectious disease caused by the varicella
zoster virus (VZV). Like other herpesviruses, VZV persists in
the body after the primary infection as a latent infection.
Primary infection with VZV results in varicella (chickenpox).
Re-activation of latent infection results in herpes zoster (HZ;
shingles).
The mode of transmission of varicella is mainly airborne.
The disease is characterized by fever and a generalized rash, in
varying stages of development and resolution. By adolescence,
90% of the population in Europe has had the disease. Although
it is mostly mild in children, complications can occur, especially
in older age groups, the fetus (congenital varicella syndrome),
newborn infants (neonatal varicella), and immunocompro-
mised patients [2].
Varicella Vaccines
The ﬁrst varicella vaccine was developed in 1974 in Japan. It is
still the only strain currently available for use in production of
varicella vaccines. Several monovalent (only varicella) and
combined (with measles, mumps and rubella, MMRV) varicella
vaccines are currently authorized in Europe.
There is growing evidence indicating that monovalent and
combined varicella vaccines are highly immunogenic, efﬁcacious
and safe in preventing varicella disease. Efﬁcacy has been shown
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to be around 70–90% against varicella disease and 95–100%
against severe varicella [3]. Additionally, a two-dose vaccination
regimen has proven to result in higher seroconversion rates and
vaccine efﬁcacy compared with a single dose administration [4].
The most common adverse reactions following varicella
vaccine are local reactions, such as pain and erythema [3];
however, after vaccination with the combined vaccine
(MMRV), a two-fold higher risk for febrile seizure after 5 to
12 days among children aged 12–23 months has been
observed in post-licensure analysis [5,6]. This means one
additional febrile seizure every 2300 children vaccinated with
the MMRV vaccine. MMRV has the great advantage of
providing four vaccines in one visit. Even though febrile
seizures are not uncommon in young children and generally
have an excellent prognosis [7], some require hospitalization
and are distressing to parents. Some countries recommend
using separate vaccines only for the ﬁrst dose, as the MMRV as
second dose is less likely to cause fever and rates of febrile
seizure are lower in older children. However, the Advisory
Committee on Immunization Practices (ACIP) in the USA does
not express a preference for use of MMRV vaccine over
separate injections of equivalent component vaccines (i.e.
MMR vaccine and varicella vaccine) [7].
A WHO position paper on varicella vaccines [8] recom-
mends that policymakers should consider varicella vaccination
in countries where varicella is a relatively important public
health and socio-economic problem (compared with other
health priorities), where the vaccine is affordable, and where
high (85–90%) and sustained vaccine coverage can be achieved
(childhood immunization with lower coverage could theoret-
ically shift the epidemiology of the disease and increase the
number of severe cases in older children and adults).
Additionally, the vaccine may be offered in any country to
individual adolescents and adults without a history of varicella.
Experience in the USA
Since 2006, the US ACIP has recommended a routine
two-dose varicella vaccination programme for children, with
the ﬁrst dose administered at 12–15 months of age and the
second dose at age 4–6 years [4]. Additionally, vaccination of
susceptible people who have close contact with persons at
high risk for serious complications of varicella is recom-
mended. The USA was the ﬁrst country to introduce universal
varicella vaccination. In fact, vaccination had started with a one
dose schedule in 1996 [9], but the 85% effectiveness of one
dose of vaccine had proved insufﬁcient to prevent transmis-
sion, especially in high-contact settings such as schools, where
small varicella outbreaks continued to occur.
The US varicella vaccination programme has dramatically
reduced varicella incidence (by 90%) as well as related
complications, hospitalizations and deaths.
Experience in the EU/EEA
Information regarding the status of the introduction of varicella
vaccination in the European Union/European Economic Area
(EU/EEA) countries is available from the Vaccine EuropeanNew
Integrated Collaboration Effort (VENICE) network and former
European network for surveillance of vaccine preventable
diseases (EUVAC.NET); both the VENICE network (in collab-
oration with the European Centre for Disease Prevention and
Control (ECDC)) and the former EUVAC.NET performed a
cross-sectional survey in 29 EU/EEA countries in 2010 [10,11].
Moreover, ECDC collects information on vaccination sched-
ules in the EU/EEA countries with the help of ECDC national
focal points [12]. The information is displayed, by country and
by disease, at ECDC’s website (http://vaccine-schedule.ecdc.
europa.eu/Pages/Scheduler.aspx), with at least annual updates.
The majority of countries in the EU/EEA (22 out of 29) have
some kind of recommendations for varicella vaccination [10]
(Fig. 1).
Five countries (Cyprus, Germany, Greece, Latvia and
Luxemburg) have a nationwide universal recommendation of
varicella vaccine for children. In Italy and Spain a universal
childhood recommendation of varicella vaccine is implemented
only in some regions.
Seventeen countries (including the two with regional
universal recommendation) recommend nationwide vaccination
for susceptible teenagers (seven countries) and/or susceptible
risk groups only (19 countries). There are seven countries with
no speciﬁc recommendation for varicella vaccination.
Information on the year of introduction of vaccine recom-
mendation, number of doses and age of varicella vaccination
for countries or regions with universal vaccination are
provided in Table 1. The ﬁrst dose is indicated between
11 months and 2 years, depending on the country. For the
countries with a two-dose schedule, the age of the second
dose varies from 15 months to 6 years.
The data show that Germany, where the vaccine was
introduced in 2004, is the European country with the largest
experience using universal varicella vaccination.
Concerns Regarding Varicella Vaccination
Varicella vaccine has an excellent safety proﬁle and high
performance. All studies available from EU countries show,
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similar to US studies, a dramatic decrease in the incidence of
varicella and varicella complications after the introduction of
vaccination into the routine schedule. So, why has there been a
laboured take-off of varicella vaccination?
As mentioned at the start of this article, reactivation of
latent infection of VZV results in HZ. Factors associated with
VZV reactivation in HZ include mainly aging and immunosup-
pression [13]. However, the immunological mechanisms that
control latency of VZV are not well understood. Cell-mediated
immunity appears to play an important role in the host
immune response to VZV [14], and development of HZ may
occur as cell-mediated immunity declines with advancing age
or other immune-suppressing factors [14–19].
Additionally, cell-mediated immunity may be boosted peri-
odically by endogenous subclinical reactivation of latent virus
or by re-exposure to exogenous virus from individuals
suffering from varicella or HZ [20]; there are studies both
supporting [21–24] and not supporting [25] this theory.
Ogunjimi et al. [26] recently published a systematic review of
the literature concluding that exogenous boosting for VZV
seems to exist, but it remains unknown to what extent it
affects HZ incidence.
Therefore, an increase in coverage of varicella vaccine, and
the consequent decrease of wild-type virus circulation, could
have a potential impact on the epidemiology of varicella and
HZ. The uncertainties regarding these potential effects are the
main reasons for the diverse current policies in the EU/EEA
countries.
Indeed, as overall disease incidence declines due to
vaccination, the VZV exposure risk decreases, leading to
susceptible children aging into adolescence and adulthood.
Accumulation of susceptible individuals may result in disease
outbreaks later in life, when varicella is more likely to be
severe. Also, in case of waning immunity, there could be
susceptible populations at older ages. Additionally, if the
exogenous boosting theory proves to be correct, low
exposure to VZV could potentially lead to an increase in HZ
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FIG. 1. Varicella vaccination recommendation in European Union/European Economic Area (EU/EEA) countries, 2012.
TABLE 1. Year of introduction, number of doses and age of
varicella vaccination in European Union and European Eco-
nomic Area/European Free Trade Association countries with
childhood universal vaccination, 2012
Year of
introduction First dose Second dose
Germany 2004a 11–14 months 15–23 months
Latvia 2008 12–15 months –
Greece 2006 12–15 months 4–6 years
Cyprus 2010 13–18 months 4–6 years
Luxemburg 2010 12 months 15–23 months
Italy
Sicily 2003 2 years –
Veneto 2005 15 months 3 years
Puglia 2010
Toscana 2010
Spain
Madrid 2006 15 months –
Navarra 2007 15 months 3 years
Ceuta 2009 18 months 24 months
Melilla 2009 15 months 24 months
aUniversal vaccination of infants with one dose was recommended in Germany in
2004, and universal vaccination with a second dose was recommended in 2009.
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incidence, as a result of the reduction of immunological
boosting caused by the varicella vaccination.
Epidemiological data from countries with experience on
varicella vaccination have not, so far, shown a shift in the age at
varicella infection, nor an increase in HZ. However, more
years need to pass to fully understand the effects of the vaccine
recommendations now in place.
Modelling Studies
To cover these uncertainties, several studies on mathematical
modelling on varicella vaccination have been conducted. These
studies use assumptions to predict what will happen in
different scenarios. It is important to take into account that
models are sensitive to the assumptions used, so these studies
should be interpreted carefully.
In the case of varicella vaccination, data on breakthrough
cases, long-term protection, importance of coverage level, and
impact on HZ data mostly come from modelling studies.
Regarding the impact of varicella vaccination on varicella
epidemiology, most models have predicted that varicella
vaccine would produce a rapid and sharp decrease of varicella
in the ﬁrst decade after vaccine introduction, which is
consistent with the available epidemiological data. If low
coverage levels are attained or if a one-dose strategy is used, a
post-honeymoon epidemic is likely to occur. A shift in the
average age of infection (with an increase in the absolute case
in adults) is expected if coverage is below 80%.
Regarding the impact of varicella vaccination on the
epidemiology of HZ, most models have predicted an increase
in the incidence of HZ in the medium term (30–75 years),
followed by a decrease (assuming contact with VZV boosts HZ
immunity).
Conversely, new models [27] have shown that an increase of
HZ incidence is not expected to occur in all countries
introducing varicella vaccination, but rather seems to depend
on the presence or absence of factors that promote a strong
intensity of boosting and so may (or may not) be heavily affected
by changes in the circulation of the virus due to vaccination
campaigns. These ﬁndings might provide an explanation for the
opposed empirical evidence generated about the increases of
HZ in sites where mass varicella vaccination is ongoing.
Countries with No Universal Recommen-
dation
The Joint Committee on Vaccination and Immunization (JCVI)
in the UK considered, between 2007 and 2009, the potential
use of varicella and herpes zoster in vaccination programmes
in the UK [28]. Data from a sentinel general practitioners
network and seroprevalence studies have shown that in the
UK most infections occur before the age of 14 years, and that
there has been an age-related change during last 20 years
towards children <5 years old, where disease is less severe.
Following these data as well as other information available, a
universal varicella vaccination for children was not recom-
mended in the UK. Nevertheless, the JCVI will keep this
recommendation under review in light of emerging data on the
epidemiology of varicella and herpes zoster infections and the
cost-effectiveness of vaccines against these infections.
In France, The ‘Haut Conseil de Sante Publique’ re-evalu-
ated in 2007 the recommendations for a vaccine against
varicella [29]. Following consideration of the US experience,
epidemiological and modelling data, data available on vaccines
and data on the potential acceptation of the vaccine in France,
they decided not to recommend universal childhood vaccina-
tion. Nevertheless, a two-dose schedule is recommended in
the country for susceptible adolescents (12–18 years) and
adults in speciﬁc risk groups (women of childbearing age,
candidates for organ transplantation, occupational risk groups
and seronegative close contact of immunosuppressed individ-
uals).
Surveillance Systems of Varicella and HZ in
the EU/EEA
Surveillance systems for vaccine-preventable diseases are
essential before a vaccine is implemented to estimate the
burden of disease and to decide on the appropriate vaccination
strategies. Additionally, post-introduction data are required to
monitor vaccine programme performance. Surveillance sys-
tems could help to assess the impact of varicella vaccination on
the epidemiology of varicella and HZ and could provide an
answer to some of the uncertainties around the vaccine.
Information regarding the surveillance systems of varicella
vaccination existing in the EU/EEA countries is available from
the VENICE and EUVAC.NET surveys [10,11].
Varicella surveillance is in place in 22 out of 29 countries
participating in the surveys. The characteristics of these
surveillance systems vary widely throughout the countries.
Fundamentally, a standardized case deﬁnition for varicella at
EU/EEA level does not exist, and countries use different
deﬁnitions. In 18 countries reporting is mandatory and it
includes all cases of varicella (comprehensive system), and in
eight countries a sentinel system is in place. Data collected
differ among countries, with some countries collecting all cases
whereas others only collect cases with complications. Also,
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data available are different: in some countries there is
information available for each case whereas in others only
aggregated information (total number) is available.
Regarding HZ surveillance, only 11 out of 29 countries have
any system in place. There is clinician-based sentinel surveil-
lance in six countries and other forms of surveillance in six
countries.
Conclusions
Varicella vaccines are highly immunogenic, efﬁcacious and safe
in preventing varicella disease. However, uncertainties over
the potential impact of varicella vaccination on the epidemi-
ology of varicella and HZ still exist. These uncertainties are the
main reason behind the heterogeneous use of varicella vaccine
in the EU/EEA countries, with some countries recommending
universal vaccination in children either nationwide or in some
regions only, others only in high-risk groups and others having
no recommendation at all.
The lack of surveillance of varicella andHZ in some countries,
as well as the high variability of surveillance systems in those
countries that have one, makes it difﬁcult to assess the effect of
the vaccine. Continuous surveillance of VZV and HZ is needed
to identify any changes in the epidemiological presentation of the
diseases. In any case, continuous surveillance will be needed to
fully describe the impact of the programmes currently running
and clarify some of the actual uncertainties in the near future.
Additionally, increasing our understanding of the risk factors for
development of HZ is required.
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